The role of serum lipid profile, fasting blood sugar, and body mass index on recurrence and metastasis in patients with estrogen receptor-positive breast cancer: A case-control study.

Breast cancer fasting blood sugar metabolic syndrome recurrence serum lipid profile

Journal

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
ISSN: 1735-1995
Titre abrégé: J Res Med Sci
Pays: India
ID NLM: 101235599

Informations de publication

Date de publication:
2023
Historique:
received: 03 03 2022
revised: 11 03 2023
accepted: 27 04 2023
medline: 31 1 2024
pubmed: 31 1 2024
entrez: 31 1 2024
Statut: epublish

Résumé

Breast cancer (BC) is the leading cause of cancer death in women. The current study is designed to evaluate the association of lipid profiles, FBS, and body mass index (BMI) with BC recurrence and metastasis. This is a case-control study on estrogen receptor-positive BC patients in Isfahan Province, Central Iran, between 2008 and 2020. The control group was patients who had no evidence of recurrence or metastasis at least 1 year after the end of chemotherapy and hormone therapy. The case group was patients with evidence of metastasis or recurrence within 1 year after the end of chemotherapy and hormone therapy. Fasting blood sugar (FBS), total cholesterol (Chol), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured before treatment, after chemotherapy, and after hormone therapy as well as BMI in the case and control groups. There were 108 patients in the case and 119 patients in the control group with a mean age of 50.72 ± 13.26 and 51.91 ± 11.79, respectively. There were no meaningful differences between the case and control groups regarding serum FBS, Chol, TG, HDL, LDL, and BMI. We found no association between serum FBS, lipid profile, and BMI at initial diagnosis and BC recurrence or metastasis.

Sections du résumé

Background UNASSIGNED
Breast cancer (BC) is the leading cause of cancer death in women. The current study is designed to evaluate the association of lipid profiles, FBS, and body mass index (BMI) with BC recurrence and metastasis.
Materials and Methods UNASSIGNED
This is a case-control study on estrogen receptor-positive BC patients in Isfahan Province, Central Iran, between 2008 and 2020. The control group was patients who had no evidence of recurrence or metastasis at least 1 year after the end of chemotherapy and hormone therapy. The case group was patients with evidence of metastasis or recurrence within 1 year after the end of chemotherapy and hormone therapy. Fasting blood sugar (FBS), total cholesterol (Chol), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured before treatment, after chemotherapy, and after hormone therapy as well as BMI in the case and control groups.
Results UNASSIGNED
There were 108 patients in the case and 119 patients in the control group with a mean age of 50.72 ± 13.26 and 51.91 ± 11.79, respectively. There were no meaningful differences between the case and control groups regarding serum FBS, Chol, TG, HDL, LDL, and BMI.
Conclusion UNASSIGNED
We found no association between serum FBS, lipid profile, and BMI at initial diagnosis and BC recurrence or metastasis.

Identifiants

pubmed: 38292335
doi: 10.4103/jrms.jrms_163_22
pii: JRMS-28-83
pmc: PMC10826846
doi:

Types de publication

Journal Article

Langues

eng

Pagination

83

Informations de copyright

Copyright: © 2023 Journal of Research in Medical Sciences.

Déclaration de conflit d'intérêts

There are no conflicts of interest.

Auteurs

Iman Mohammadbeigy (I)

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Mohammad Sadegh Khalilian (MS)

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Nadia Najafizadeh (N)

Department of Radiation Oncology, Seyed Al-Shohada (Omid) Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Elham Moazam (E)

Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Simin Hemati (S)

Department of Radiation Oncology, Seyed Al-Shohada (Omid) Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Mehrdad Zeinalian (M)

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Iranian Cancer Control Center (MACSA), Isfahan, Iran.

Classifications MeSH